Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology. Cutaneous T ...

People attending a football match will be asked to sign up to a stem cell register in the hope of finding a donor for a local ...

A fusion protein therapy may be an effective treatment option for cutaneous T-cell lymphomas, according to a multicenter clinical trial published in the Journal of Clinical Oncology.

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at ...

Cutaneous T-cell lymphoma is a group of rare blood cancers that affects the skin. Nine patients have been enrolled and treated with H By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH ...

Soligenix, Inc. (NASDAQ: SNGX) decreased in price early Tuesday, as the late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an ...

Equillium, Inc. , a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, and ...